ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: 37 years Female

Specimen Collected: 20-Mar-23 14:26

Drug Panel 9, Urn, Scrn w/Rflx to Conf | **Received: 23-Mar-23 14:29** | **Report/Verified: 23-Mar-23 15:40**

Procedure	Result	Units	Reference Interval
Creatinine,Urine	113.9	mg/dL	[20.0-400.0]

Drug Panel 9, Urn, Scrn w/Rflx to Conf | **Received: 23-Mar-23 14:29** | **Report/Verified: 23-Mar-23 15:41**

Procedure	Result	Units	Reference Interval
Amphetamines,Urn,Screen	Negative	ng/mL	[Cutoff 300]
Barbiturates,Urn,Screen	Negative	ng/mL	[Cutoff 200]
Benzodiazepines,Urn,Screen	Negative	ng/mL	[Cutoff 200]
Cocaine,Urn,Screen	Negative	ng/mL	[Cutoff 150]
Methadone,Urn,Screen	Negative	ng/mL	[Cutoff 150]
Opiates,Urn,Screen	Positive	ng/mL	[Cutoff 300]
Phencyclidine,Urn,Screen	Negative	ng/mL	[Cutoff 25]
Propoxyphene,Urn,Screen	Negative	ng/mL	[Cutoff 300]
THC,Urn,Screen	Negative	ng/mL	[Cutoff 50]
CDASU 9 Comments	See Note [i1]		

Opiates, Urn, Quant | **Received: 23-Mar-23 14:29** | **Report/Verified: 23-Mar-23 15:42**

Procedure	Result	Units	Reference Interval
6-acetylmorphine,Urn,Quant	<10 [i2]	ng/mL	
Codeine,Urn,Quant	<20	ng/mL	
Hydrocodone,Urn,Quant	1242	ng/mL	
Hydromorphone,Urn,Quant	<20	ng/mL	
Morphine,Urn,Quant	<20	ng/mL	
Norhydrocodone,Urn,Quant	818 [f1]	ng/mL	
Noroxycodone,Urn,Quant	<20	ng/mL	
Noroxymorphone,Urn,Quant	<20	ng/mL	
Oxycodone,Urn,Quant	<20	ng/mL	
Oxymorphone,Urn,Quant	<20	ng/mL	

Result Footnote

f1: Norhydrocodone, Urn, Quant

Norhydrocodone is a metabolite of hydrocodone; consistent with use of a drug containing hydrocodone. Hydrocodone may also be a metabolite of codeine, or an impurity of oxycodone.

Test Information

i1: CDASU 9 Comments

INTERPRETIVE INFORMATION: Drug Panel 9, Urn, Scrn w/Rflx to Conf

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS

Test Information

i1: CDASU 9 Comments

and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Oxycodone results are reported with the opiates results. MDMA results are reported with the amphetamines results. The following opioids are not detected in this test: fentanyl, buprenorphine, meperidine, tramadol, and tapentadol. A comprehensive panel that includes these opioids is available or individual opioid testing can be ordered. Refer to aruplab.com for test information.

For medical purposes only; not valid for forensic use.

i2: 6-acetylmorphine, Urn, Quant

INTERPRETIVE INFORMATION: Opiates, Urine, Quantitative

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff: 20 ng/mL except as specified below

6-acetylmorphine	10 ng/mL

For medical purposes only; not valid for forensic use.

Identification of specific drug(s) taken by specimen donor is problematic due to common metabolites, some of which are prescription drugs themselves. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. All drug analytes covered are in the non-glucuronidated (free) forms. The concentration value must be greater than or equal to the cutoff to be reported as positive. A very small amount of an unexpected drug analyte in the presence of a large amount of an expected drug analyte may reflect pharmaceutical impurity. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.